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Background and aims: Pentraxin-3 (PTX3) reportedly has protective roles in atherosclerosis and myocardial
infarction, and is a useful biomarker of vascular inﬂammation. However, the detailed functions of PTX3 in
inﬂammation are yet to be elucidated. This study aimed to investigate the function of PTX3 in macrophages.
Methods: PMA-treated THP-1 cell line (THP-1 macrophage) and monocyte-derived human primary macro-
phages were treated with recombinant PTX3. Cytokine and chemokine levels in the THP-1 culture medium
were measured as well as monocyte chemoattractant protein (MCP-1) concentrations in the Raw 264.7 cell
culture medium. PTX3-silenced apoptotic macrophages (THP-1 cell line) were generated to investigate the
roles of PTX3 in phagocytosis.
Results: In the presence of PTX3, macrophage interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α)
and MCP-1 levels were reduced signiﬁcantly (39%, P¼0.007; 21%, P¼0.008; and 67%, P¼0.0003, re-
spectively), whilst activated transforming growth factor-β (TGFβ) was detected in the THP-1 macrophages
(P¼0.0004). Additionally, PTX3 induced Akt phosphorylation and reduced nuclear factor-kappa B (NF-κB)
activation by 35% (P¼0.002), which was induced by TNF-α in THP-1 macrophages. Furthermore, silencing of
PTX3 in apoptotic cells resulted in increased macrophage binding, elevated expression rate of HLA-DR
(þ30%, P¼0.015) and CD86 (þ204%, P¼0.004) positive cells, and induction of IL-1β (þ36%, P¼0.024)
production. Conversely, adding recombinant PTX3 to macrophages reduced CD86 and HLA-DR expression in
a dose-dependent manner.
Conclusions: We identiﬁed PTX3 as a novel regulator of macrophage activity, and this function suggests that
PTX3 acts to resolve inﬂammation.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Inﬂammation, resolution of inﬂammatory processes and tissue
repair, are pivotal factors in many diseases. When inﬂammation
occurs, many cytokines and mediators, including pentraxins, are
produced as needed for the immune response. During healing,
positive processes are evoked to resolve the inﬂammation and
activate multiple inhibitory pathways, including local transform-
ing growth factor-beta (TGF-β) activation, recruitment of sup-
pressive monocytes and upregulation of M2 macrophages and
regulatory T cells, which can produce and secrete inhibitory
mediators such as TGF-β and interleukin (IL)-10 [1].
Pentraxins are a superfamily of pattern recognition proteins
that constitute the prototypic components of the humoral arm of
the innate immune system. C-reactive protein (CRP) and serumr B.V. This is an open access article
aki),amyloid P component (SAP) are short pentraxins produced by the
liver. In contrast, pentraxin-3 (PTX3) was the ﬁrst long pentraxin
identiﬁed as an IL-1-inducible protein in endothelial cells and a
tumor necrosis factor (TNF)-stimulated protein in ﬁbroblasts [2,3].
PTX3 assembles into a four protein tetramer, with two links
together forming an octameric structure [4]. PTX3 recognizes pa-
thogen-associated molecular patterns. Moreover, it interacts with
C1q, ﬁcolin-1, ﬁcolin-2 and mannose-binding lectin, all of which
are recognition molecules in the classical and lectin complement
pathways [3]. Furthermore, PTX3 has been found to have sig-
niﬁcant interaction with ﬁbroblast growth factor (FGF)-2 [5], Fcγ
receptor [6] and P-selectin [7].
PTX3-deﬁcient mice exhibit exacerbated myocardial damage
following coronary artery ligation and reperfusion associated with
greater no-reﬂow areas, increased neutrophil inﬁltration, de-
creased numbers of capillaries and increased numbers of apoptotic
cardiomyocytes [8]. Moreover, double-knockout mice, lacking
PTX3 and apolipoprotein E, exhibit increased atherosclerosis and
macrophage accumulation in atherosclerotic lesions comparedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. rPTX3 reduced inﬂammatory cytokines and induced active TGF-β (A) THP-1 macrophage-conditioned culture medium was assessed for cytokines using the Luminex
system. The culture medium was serum-depleted and incubated with THP-1 cells for 24 h with (grey columns) or without 10 ng/mL rPTX3 (black columns), (means7SD,
n¼8; **po0.01); (B) rPTX3 reduced MCP-1 production by murine Raw 264.7 macrophage cells, activated by 20 nM of PMA and cultured with or without human rPTX3 for
24 h. The cultured medium was collected and measured using ELISA (means7SD, n¼8; *po0.05, **po0.001). PMA: phorbol-myristate-acetate.
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Fig. 2. rPTX3 modulated intracellular signaling. Western blotting displayed in-
creased phosphorylation of Akt in THP-1 macrophages. The graphs show the
densitometry value analysis of western blots. The western blots were performed at
least three times (**po0.001).
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Fig. 3. rPTX3 reduced TNFα-induced NFκB activation. HUVECs were transfected
with pGL4.32[luc2P/NFκB-RE/Hygro] reporter vector and TNF-α was added. Pre-
treatment with rPTX3 reduced NF-κB activation (means7SD, n¼5; **po0.001 vs.
TNF-α(þ)).
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gesting that PTX3 possesses a cardiovascular protective function
[9]. Furthermore, PTX3 is also reported to be expressed in ather-
omas [10,11]. However, the detailed mechanisms underlying these
functions of PTX3 remain to be elucidated.
In clinical studies, the usefulness of PTX3 as a biomarker has
emerged in many diseases, including unstable angina pectoris [12],
acute coronary syndrome [13], chronic heart failure [14], heart
failure with a normal ejection fraction [15], and Takayasu arteritis
[16]. Upregulation of PTX3 in the serum is considered to be an
indicator of vascular inﬂammation [17]; however, little evidence is
available regarding the role and results of PTX3 upregulation.
Although some studies have been carried out to investigate the
relationship between PTX3 and macrophages, the function of PTX3
in macrophages has not been studied to date. In the present study,
we investigated the inﬂuence of PTX3 in macrophages in vitro, and
found that it regulated inﬂammatory activities of these cells.2. Materials and methods
2.1. Ethics statement
The research met all applicable standards for the ethics of ex-
perimentation and was approved by the Ethics Committee of the
Faculty of Medicine of Saga University (No. 26-56). Participants
provided written informed consent prior to the experiment.2.2. Cell culture and materials
Cells were cultured at 37 °C under 5% CO2. The human THP-1
cell line was purchased from Riken Bioresource Center (RCB1189).
THP-1 cells were cultured in RPMI medium with 10% fetal bovine
serum (FBS). THP-1 macrophages were generated by incubating
the cells with 100 nmol/L of phorbol-myristate-acetate (PMA) for
24 h. Raw 264.7 cells were purchased from ATCC and cultured in
DMEM with 2 mM Glutamine and 10% Foetal Bovine Serum (FBS).
Recombinant PTX3 (rPTX3) was provided by Perseus Proteomics
Inc. (Tokyo, Japan). It was made by the procedure that was written
in the article [12]. Human umbilical vein endothelial cells (HU-
VECs) and speciﬁc medium for HUVEC culture were obtained from
Lonza (Basel, Swiss). Experiments using HUVECs were conducted
with cells between passage numbers three and ﬁve (P3–P5). Hu-
man monocyte-derived macrophages were generated from heal-
thy volunteers' blood.
Peripheral blood mononuclear cells (PBMC) were separated
using Ficoll-Paque PLUS solution and lymphocytes were washed
away after monocyte adhesion on tissue culture-treated culture
plates. Cells were cultured with 20 ng/mL of granulocyte macro-
phage-colony stimulating factor (GM-CSF, Pepro Tech, Rocky Hill,
NJ) in RPMI medium containing 10% FBS and were incubated for
6 days prior to assaying. TGF-β neutralizing antibody was obtained
from R&D Systems (Minneapolis, MN. Ab-100-NA rabbit poly-
clonal, 10 mg/mL).
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Fig. 4. Silencing PTX3 in apoptotic cells raised the afﬁnity for macrophages and attenuated inﬂammatory responses. (A) Binding of apoptotic bodies on phagocytes was
elevated in PTX3(-) THP-1 cells (means7SD, n¼8, *po0.005). (B,C) Immunocytochemistry of phagocytic THP-1 macrophages. HLA-DR and CD86 were immunostained with
Alexa Fluoro 568 secondary antibody (red). Hoechst 33342 (blue) was used for nuclear staining. Photos: upper left, merged image; upper right, HLA-DR or CD86; lower left,
Hoechest 33342; lower right, phase-contrast image. Bar, 0.3 mm. Positive cells were counted and normalized to the number of the cells present to generate the percentage
using Image-J (means7SD, n¼8; *po0.05). (D) IL-1β concentration in cultured medium (means7SD, n¼8; *po0.05).
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THP-1 macrophages were lysed with RIPA buffer containing
sodium ﬂuoride (NaF), trypsin inhibitor, leupeptin, β-glyceropho-
sphate and orthovanadate. Lysates of samples were resolved on
SDS-PAGE according to standard protocol. The used protein
amount was 40 μg/lane. After being transferred to membranes,
samples were immunoblotted with primary antibodies (see be-
low) followed by secondary antibodies conjugated to horseradish
peroxidase (NA934V anti-rabbit IgG, NA931V anti-mouse IgG, GE
Healthcare, Buckinghamshire, UK). Bands were revealed using ECL
Plus Western Blotting Detection Reagents or ECL Advance Western
Blotting Detection Reagents (GE Healthcare, Buckinghamshire,
UK). The band density was quantiﬁed using Image J software [18].
The following primary antibodies were used: anti-p-Akt (#9271
rabbit polyclonal, 1:50), anti-Akt (#9272 rabbit polyclonal, 1:1000),
which were purchased from Cell Signaling (Danvers, MA). Actin (I-
19): (sc-1616-R, rabbit polyclonal, 1:1000) was from Santa Cruz
Biotech (Santa Crus, CA). All western blots were performed at least
three times.2.4. Cytokine measurements
TNF-α, IL-1β, monocyte chemoattractant protein-1 (MCP-1),
active TGF-β and IL-10 were measured in the culture medium
using the Luminex 100 system (Luminex Corporation, Austin, TX).
Anti-human Procarta Cytokine Plex kits (PN-PC1004) were pur-
chased from Veritas (Tokyo, Japan). Some data for murine MCP-1
and human IL-1β were obtained from enzyme-linked im-
munosorbent assays (ELISA) using commercially available kits
from eBioscience (San Diego, CA). To measure active TGF-β, sam-
ples were not put through an acidifying and neutralizing
procedure.
2.5. NF-κB activation
To study NF-κB activation, HUVECs were transiently transfected
with the pGL4.32[luc2P/NFκB-RE/Hygro] vector, containing ﬁve
copies of the NF-κB response elements, to drive transcription of
the luciferase reporter gene luc2P. This NF-κB-RE reporter plasmid
was transfected by electroporation, together with the phRL-CMV
plasmid that is renilla luciferase control reporter vector, into
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Fig. 5. rPTX3 reduced HLA-DR and CD86 expression in human monocyte-derived macrophages. Macrophages were generated from monocytes cultured with 20 ng/mL GM-
CSF for 6 days and incubated with rPTX3 for another 24 h. (A,C) Representative data of ﬂow cytometric histograms of human macrophages. Filled histograms, isotype IgG;
dotted line, control; solid line, PTX3 1 mg/mL. (B and D) Geometric means of HLA-DR and CD86 on macrophages (means7SD, n¼3–8; **po0.005,*po0.05).
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BioRad, Hercules, CA). The cells were cultured overnight and
starved in RPMI-1640 medium containing 0.1% FBS, heparin
(500 m/L) and endothelial cell growth factor (ECGF, 2 mg/L) for 1 h
and pre-incubated with either rPTX3 (100 ng/mL) or vehicle for
30 min. The cells were then stimulated with TNF-α (5 ng/mL) for
6 h. Luciferase activity was then measured with the Dual-Lucifer-
ase Reporter Assay System (Promega, Madison, WI) and expression
levels of luc2P (Photinus pyralis) was standardized by the renilla
luciferase activity.
2.6. Silencing PTX3 and inducing apoptosis in THP-1 cells
THP-1 cells were seeded at 80,000 cells/well in 96-well plates
and incubated with 100 nM PMA overnight. Wells were rinsed
twice with RPMI-1640 containing L-glutamine and 10% FBS and
replaced with 100 μL medium. The siRNA for PTX3 and control
siRNA were purchased from Santa Cruz Biotechnology (sc-39187
and sc-37007, respectively, Dallas, Texas). siRNA (13.3 pmol/well)
was diluted in 25 μL Opti-Mem medium. Lipofectamines (1.66 mL)
RNAiMAX Transfection Reagent, purchased from Life Technologies
(Carlsbad, California), was diluted in 25 μL Opti-Mem medium and
these two dilutions were mixed gently and incubated for 10–
20 min at room temperature. This 50-μL mixture was then added
to THP-1 macrophages generated in 96-well plates. The cells were
incubated for 24 h at 37 °C in a CO2 incubator. The knockdown
efﬁcacy was 85% when stimulated by lipopolysaccharide (LPS)
(Supplementary data), which was determined by a PTX3 ELISA
purchased from Perseus Proteomics (Tokyo, Japan).
2.7. Apoptotic cell generation and binding assay
THP-1 macrophages were treated with siRNA to reduce levels
of PTX3 expression. PTX3-low and PTX3-normal macrophages
were then exposed to UV irradiation (302 nm, 0.07 w/cm2) for10 min to induce apoptosis. These apoptotic macrophages were
immediately stained with Cell Tracker Blue (Invitrogen) and added
to a monolayer of THP-1 macrophages in 96-well plates and in-
cubated for 24 h. Non-adherent apoptotic macrophages were wa-
shed twice with RPMI medium and photos were captured by a
FSX100 microscope (Olympus, Japan).
2.8. Immunocytochemistry
THP-1 cells were ﬁxed with 10% neutral buffered formalin
ﬁxative and rinsed with phosphate buffered saline (PBS). Non-
permeabilized cells were blocked with PBS containing 3% bovine
serum albumin (BSA). Cells were incubated with primary anti-
bodies to HLA-DR (12-9956, mouse monoclonal, 1:20) and CD86
(12-0869 mouse monoclonal,1:5) (eBioscience, San Diego, CA).
Cells were then rinsed and incubated with secondary antibody
(A11061 rabbit polyclonal anti-mouse IgG, Alexa Fluor 568, In-
vitrogen) at room temperature for 30 min. Hoechst 33342 (In-
vitrogen) was used for nuclear staining and images were captured
by a FSX100 microscope. Positive cells were analyzed with Image-J
software.2.9. Flow cytometry
Human monocyte-derived macrophages were washed twice
with PBS and incubated in PBS/EDTA for 10 min prior to collection.
HLA-DR-FITC antibody (eBioscience, 11-9956 mouse monoclonal,
2.5 mL/test) and CD86-PE antibody (eBioscience, 12-0869 mouse
monoclonal, 2.5 mL/test) were incubated with the samples for
30 min. Those samples were washed twice with 1%FBS/PBS. The
antibodies of isotype controls were also used. FITC and PE levels
were measured by the MACSQuant analyzer (Miltenyi Biotec.
Germany).
A. Shiraki et al. / Biochemistry and Biophysics Reports 5 (2016) 290–2952942.10. Statistical analysis
Data are expressed as the means7standard deviation (SD).
Student's t test was used to determine differences between two
population averages. Data comparisons between groups were
carried out using one-way analysis of variance (ANOVA) with a
Bonferroni post-hoc test. A P value less than 0.05 was deemed to
be statistically signiﬁcant. All statistical analyses were performed
using the Statistical Package for the Social Sciences (SPSS 16.0 Ja-
panese edition for Windows, SPSS Inc. Tokyo, Japan).3. Results
3.1. rPTX3 reduced pro-inﬂammatory cytokines and induced active
TGF-β in THP-1 cells
To elucidate the role of protein PTX3 in macrophages, one of
the main players in atherosclerosis, human rPTX3 was used. Fol-
lowing serum depletion for 1 h, THP-1 macrophages were treated
with 10 ng/mL of rPTX3 and the cells were incubated for 24 h. We
used a PTX3 concentration of 10 ng/mL because this is the re-
ported concentration level in human blood when inﬂammation
occurs, such as during acute myocardial infarction [19].
The Luminex assay showed that rPTX3 reduced the pro-in-
ﬂammatory cytokines TNF-α, IL-1β and MCP-1 (Fig. 1A). To assess
the quantity of originally active TGF-β, acidifying and neutralizing
procedures were omitted before the Luminex assay. Consequently,
rPTX3 was able to induce active TGF-β. Interestingly, IL-10 was not
detectable in the cultured medium.
To clarify whether rPTX3 acted in the same way in different
types of macrophages, we activated murine Raw 264.7 cells with
20 mol/L of PMA and treated them with 10 ng/mL or 100 ng/mL of
rPTX3. We found that exposure to rPTX3 reduced the concentra-
tion of MCP-1 in the culture medium of Raw 264.7 cells (Fig. 1B).
The murine MCP-1 ELISA assay was chosen because larger differ-
ences in MCP-1 levels by human THP-1 macrophages were de-
tected using the Luminex assay.
3.2. rPTX3 induced phosphorylation of Akt in THP-1 cells
We investigated intracellular signaling in THP-1 macrophages
to detect any cellular responses following PTX3 treatment. Sur-
prisingly, rPTX3 treatment of THP-1 macrophages obviously in-
duced phosphorylation of Akt in 10 min (Fig. 2).
3.3. rPTX3 reduced TNF-α-induced NF-κB activation
Next, we determined whether NF-κB activation was involved in
the rPTX3-mediation process. A luciferase reporter assay was
performed by transfecting pGL4.32[luc2P/NFκB-RE/Hygro] vectors
into HUVECs. The activation level of NF-κB induced by TNF-α was
reduced by rPTX3 (34%, P¼0.002) (Fig. 3).
3.4. Silencing PTX3 enhanced inﬂammatory responses in THP-1
macrophages
To further elucidate the effects of PTX3, we developed an assay
to determine how the knockdown of PTX3 expression in apoptotic
cells might affect the binding and engulfment ability of macro-
phages and the inﬂammatory response. PTX3-low macrophages
were generated by siRNA and the cells were then treated with UV
to induce apoptosis. As a result, PTX3-low apoptotic cells bound to
macrophages at more than twice the frequency of PTX3-normal
apoptotic cells (Fig. 4A). The macrophages that engulfed apoptotic
bodies were analyzed by staining for HLA-DR and CD86. Thefrequencies of HLA-DR- and CD86-positive cells were signiﬁcantly
elevated in macrophages that engulfed PTX3-low apoptotic bodies
(Fig. 4B and C). IL-1β was also upregulated in the culture medium
in the PTX3-low group (Fig. 4D).
3.5. rPTX3 regulated expression of HLA-DR and CD86 in
macrophages
We attempted to clarify the mechanism by which PTX3-silen-
cing upregulated HLA-DR and CD86. We therefore investigated if
rPTX3 reduced HLA-DR and CD86 expression in macrophages. To
obtain a homogeneous population of macrophages and to ensure
rPTX3 could work effectively on primary macrophages, human
monocyte-derived macrophages were generated. On the 6th day,
human monocyte-derived macrophages were cultured with
1 mg/mL rPTX3 for 24 h. Expression levels of HLA-DR and CD86
were signiﬁcantly reduced by rPTX3 (Fig. 5). Furthermore, treat-
ment with TGF-β neutralizing antibody did not reverse this effect.4. Discussion
This report demonstrates that PTX3 promoted activated TGF-β
and induced anti-inﬂammatory responses in macrophages. This
anti-inﬂammatory property is a novel function of PTX3 that may
play an important role in inﬂammation and the subsequent healing
process. In this report, human recombinant PTX3 was also treated
in RAW 264.7 cells, which were mouse origin, and it worked. Ori-
ginally, the protein PTX3 was well conserved through species and
the identity of protein PTX3 between human and mouse was 82%.
Here, we investigated the function of PTX3 in macrophages.
Surprisingly, the levels of pro-inﬂammatory cytokines released
from macrophages decreased in the presence of rPTX3. Moreover,
active TGF-β was detected in serum-free culture medium. This
result suggests that PTX3 acts to suppress the activity of macro-
phages at inﬂamed sites. Recently, it was reported that 50% of
PTX3-positive macrophages in coronary atherosclerosis were M2
type [10]. Moreover, Hua et al. reported that heavy chain–hya-
luronic acid complex (HC–HA), puriﬁed from the human amniotic
membrane, contains PTX3, induces TGF-β1 and reduces TNF-α in
RAW264.7 cells [20]. They also found that the HC–HA-PTX3
complex is produced by amniotic membrane cells and propose
that it has a protective role in fetal development. Interestingly,
amniotic membrane is used in various operative situations, such as
amniotic membrane grafting in ophthalmologic procedures and in
the dressing of burns, because it has anti-inﬂammatory, anti-
scarring and anti-angiogenic actions. Our ﬁnding showed that
PTX3 itself suppressed macrophage pro-inﬂammatory activity,
which may be one explanation of the protective role of the am-
niotic membrane during fetal development and wound healing.
Activation of TGF-β is promoted by a wide range of factors,
including proteases, physiochemical mediators and binding of
other proteins, such as thrombosponsin-1 and integrins [21]. In
this study, we detected active TGF-β within macrophage culture
medium after adding rPTX3. Unfortunately, it remains unclear how
TGF-β was activated by PTX3 under these conditions. The upre-
gulation of TGF-β was not responsible for the reduction of HLA-DR
and CD86 expression by human macrophages. Thus, the signaling
pathway used by rPTX3 in macrophages remains to be identiﬁed.
Our observation that PTX3 modulated intracellular signaling by
p-Akt is novel. However, we did not do further experiments using
inhibitors of Akt such as wortmannin and LY294002, because
macrophages and HUVECs did not survive with those inhibitors
when incubation periods were over 12 h, that was necessary for
the expressions of property of rPTX3. The roles of Akt activation
remained to be elucidated.
A. Shiraki et al. / Biochemistry and Biophysics Reports 5 (2016) 290–295 295Other researchers have reported the existence of cellular re-
ceptors for PTX3 in macrophages [22]. Although PTX3 has also
been reported to interact with the Fcγ receptor, it remains to be
established whether other PTX3 receptors exist [4].
Some studies have reported that PTX3 can act directly on cells.
For example, PTX3 inhibits phagocytosis of late apoptotic cells by
macrophages [23] and dendritic cells (DCs) [24], although the
underlying mechanisms are not clear. In view of these ﬁndings,
our results showed that silencing of PTX3 caused increased bind-
ing of apoptotic bodies on macrophages, indicating PTX3 also has
an inhibitory effect on phagocytosis.
In our experiments, rPTX3 decreased membrane expression of
CD86 and HLA-DR/HLA-class II in human-derived macrophages.
Baruah et al., have shown that PTX3 inﬂuences membrane ex-
pression of CD86 and MHC class I and II on DCs when activated by
LPS [25]. We believe a similar phenomenon has been observed
here with macrophages, although the decreased expression of
CD86 and HLA-DR could be observed without LPS stimulation. To
elucidate the possible involvement of TGF-β activation, TGF-β-
neutralizing antibody was used. The regulation of cell surface
markers by PTX3 seemed to be independent of TGF-β because they
were not affected by TGF-β blockage.
During acute inﬂammation, the blood concentration of PTX3
rapidly elevates. For instance, plasma PTX3 levels rise during early
acute myocardial infarction [26]. This is most likely due to release
of activated neutrophils. The upregulation of PTX3 can be attrib-
uted to transcriptional factors such as NF-κB in monocytes, mac-
rophages and endothelial cells.
Our ﬁndings suggest that PTX3 attenuates and regulates ex-
cessive inﬂammatory activity in macrophages and promotes the
healing process. We propose that PTX3 could be a new treatment
for acute inﬂammation, especially in macrophage-related wounds,
such as following myocardial infarction, in atherosclerotic lesions,
and in systemic inﬂammation in which macrophages participate.
PTX3 attenuated inﬂammatory activity in cultured macro-
phages. These functional results suggest that PTX3 may participate
in the regulation of inﬂammation.Acknowledgements
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